Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Q4 2022 Neurocrine Biosciences Inc Earnings Call Transcript

Feb 06, 2023 / 01:00PM GMT
Release Date Price: $105.02 (-4.55%)
Operator

Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year-end Results. (Operator Instructions) Please note, this call may be recorded (Operator Instructions) It is now my pleasure to turn the call over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Todd Tushla
Neurocrine Biosciences, Inc.

Thank you, and a good Monday morning to everyone. Welcome to Neurocrine's Fourth Quarter and Full Year 2022 Earnings Call. I'm joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.

During this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We'll be jumping into Q&A after prepared remarks, and as is customary, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot